JAZZ · Insider Trading
Jazz Pharmaceuticals, Inc.
Every open-market purchase and sale reported by JAZZ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Neena M Patil | EVP & Chief Legal Officer | Sell | −1,200 | −$289.13K |
| 2026-09-10 | Renee D Gala | President & CEO | MIXED | −3,967 | −$971.54K |
| 2026-09-10 | Mary Elizabeth Henderson | SVP, Technical Operations | F | −1,427 | −$346.78K |
| 2026-09-02 | Bruce C Cozadd | Director | MIXED | −7,219 | −$1.80M |
| 2026-09-02 | Patrick G Enright | Director | F | −1,706 | −$411.86K |
| 2026-09-02 | Laura Hamill | Director | F | −1,706 | −$411.85K |
| 2026-09-02 | Norbert G Riedel | Director | F | −1,706 | −$411.86K |
| 2026-09-02 | Mary Elizabeth Henderson | SVP, Technical Operations | F | −2,092 | −$505.04K |
| 2026-09-02 | Heather Ann McSharry | Director | F | −1,855 | −$447.83K |
| 2026-09-02 | Ted W Love | Director | F | −743 | −$179.37K |
| 2026-09-02 | Patrick Kennedy | Director | F | −1,855 | −$447.82K |
| 2026-09-02 | Jennifer E. Cook | Director | F | −1,706 | −$411.85K |
| 2026-09-02 | Mark Douglas Smith | Director | F | −1,706 | −$411.86K |
| 2026-09-02 | Rick E Winningham | Director | F | −1,706 | −$411.86K |
| 2026-08-31 | Robert Iannone | EVP, Global Head of R&D & CMO | MIXED | −19,421 | −$11.97M |
| 2026-08-07 | Patrick Kennedy | Director | A | +1,605 | — |
| 2026-08-07 | Seamus Mulligan | Director | A | +1,605 | — |
| 2026-08-07 | Laura Hamill | Director | A | +1,605 | — |
| 2026-08-07 | Heather Ann McSharry | Director | A | +1,605 | — |
| 2026-08-07 | Jennifer E. Cook | Director | A | +1,605 | — |
| 2026-08-07 | Mark Douglas Smith | Director | A | +1,605 | — |
| 2026-08-07 | Samantha Pearce | EVP, Chief Commercial Officer | F | −780 | −$204.06K |
| 2026-08-07 | Norbert G Riedel | Director | A | +1,605 | — |
| 2026-08-07 | Ted W Love | Director | A | +1,605 | — |
| 2026-08-07 | Bruce C Cozadd | Director | A | +1,605 | — |
| 2026-08-07 | Patrick G Enright | Director | A | +1,605 | — |
| 2026-08-07 | Rick E Winningham | Director | A | +1,605 | — |
| 2026-08-07 | Patrick Kennedy | Director | A | +1,605 | — |
| 2026-08-07 | Norbert G Riedel | Director | A | +1,605 | — |
| 2026-08-07 | Patrick G Enright | Director | A | +1,605 | — |
| 2026-08-07 | Samantha Pearce | EVP, Chief Commercial Officer | F | −780 | −$204.06K |
| 2026-08-07 | Laura Hamill | Director | A | +1,605 | — |
| 2026-08-07 | Bruce C Cozadd | Director | A | +1,605 | — |
| 2026-08-07 | Mark Douglas Smith | Director | A | +1,605 | — |
| 2026-08-07 | Seamus Mulligan | Director | A | +1,605 | — |
| 2026-08-07 | Ted W Love | Director | A | +1,605 | — |
| 2026-08-07 | Jennifer E. Cook | Director | A | +1,605 | — |
| 2026-08-07 | Rick E Winningham | Director | A | +1,605 | — |
| 2026-08-07 | Heather Ann McSharry | Director | A | +1,605 | — |
| 2026-08-05 | Bruce C Cozadd | Director | Sell | −6,000 | −$1.52M |
| 2026-07-06 | Bruce C Cozadd | Director | Sell | −6,000 | −$1.44M |
| 2026-07-02 | Robert Iannone | EVP, Global Head of R&D & CMO | F | −3,764 | −$894.78K |
| 2026-07-02 | Samantha Pearce | EVP, Chief Commercial Officer | F | −2,527 | −$600.72K |
| 2026-07-02 | Renee D Gala | President & CEO | F | −4,835 | −$1.15M |
| 2026-07-02 | Neena M Patil | EVP & Chief Legal Officer | F | −2,678 | −$636.61K |
| 2026-07-02 | Philip L Johnson | EVP & Chief Financial Officer | F | −3,343 | −$794.70K |
| 2026-06-17 | Mark Douglas Smith | Director | Sell | −1,157 | −$266.75K |
| 2026-06-12 | Neena M Patil | EVP & Chief Legal Officer | Sell | −1,200 | −$278.20K |
| 2026-06-05 | Renee D Gala | President & CEO | G | −600 | — |
| 2026-06-03 | Bruce C Cozadd | Director | Sell | −6,000 | −$1.41M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Seamus Mulligan | Director | 1,286,254 | $303.13M |
| Bruce C Cozadd | Director | 351,875 | $82.93M |
| Renee D Gala | President & CEO | 143,394 | $33.79M |
| Robert Iannone | EVP, Global Head of R&D & CMO | 111,223 | $26.21M |
| Philip L Johnson | EVP & Chief Financial Officer | 56,431 | $13.30M |
| Neena M Patil | EVP & Chief Legal Officer | 47,671 | $11.23M |
| Samantha Pearce | EVP, Chief Commercial Officer | 47,131 | $11.11M |
| Kenneth W O'Keefe | Director | 30,256 | $7.13M |
| Mary Elizabeth Henderson | SVP, Technical Operations | 23,830 | $5.62M |
| Patrick G Enright | Director | 21,278 | $5.01M |
| Norbert G Riedel | Director | 19,245 | $4.54M |
| Heather Ann McSharry | Director | 18,199 | $4.29M |
| Anne ORiordan | Director | 16,500 | $3.89M |
| Jennifer E. Cook | Director | 12,428 | $2.93M |
| Mark Douglas Smith | Director | 11,271 | $2.66M |
| Rick E Winningham | Director | 9,480 | $2.23M |
| Patrick Kennedy | Director | 8,292 | $1.95M |
| Laura Hamill | Director | 6,832 | $1.61M |
| Patricia Carr | SVP, Chief Accounting Officer | 6,512 | $1.53M |
| Ted W Love | Director | 3,126 | $736.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JAZZ quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.